Journals / Dicle Tıp Dergisi / 2023 / Cilt: 50 Sayı: 2 - Cilt 50, Sayı 2

Clinical Results of Combined Systemic Steroid and Retroorbital Radiotherapy Treatment in Active Thyroid Associated Ophthalmopathy

Pages
149–155
Publication Date
2023-06-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the 6-month follow-up significant decrease in clinical activity score and improvement in diplopia was observed in addition to improvement in best corrected visual acuity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to evaluate the efficacy of a different steroid dosage protocol which consists of intravenous pulse methylprednisolone combined with retroorbital radiotherapy in the treatment of active thyroid associated ophthalmopathy.
📊
Key Findings & Data:Methods: The medical records of 29 patients who were treated with a standard protocol and who were followed-up for at least 6 months were retrospectively analyzed.
💡
Conclusion & Impact:In the 6-month follow-up significant decrease in clinical activity score and improvement in diplopia was observed in addition to improvement in best corrected visual acuity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Orbital radiotherapy · Thyroid ophthalmopathy · Graves’ disease

Abstract

Objective: The aim of this study is to evaluate the efficacy of a different steroid dosage protocol which consists of intravenous pulse methylprednisolone combined with retroorbital radiotherapy in the treatment of active thyroid associated ophthalmopathy. Methods: The medical records of 29 patients who were treated with a standard protocol and who were followed-up for at least 6 months were retrospectively analyzed. The treatment protocol consisted of intravenous pulse methylprednisolone 1gram/day for 3 consecutive days, followed by retroorbital radiotherapy. Oral prednisolone which was tapered over a 3-month course was given as a maintenance dose. Results: 58 eyes of 29 patients were included in the study. Twelve patients were female (41%) and 17 were male (59%) with a mean age of 47.7 ± 12.6 years. The clinical activity score was 4.8 ± 1.3 and 2.8 ± 1.2, before and after treatment, respectively (P <0.05). 14 eyes (31%) had an improvement in best corrected visual acuity. In 28 eyes with had proptosis, proptosis regressed after treatment. Among 21 patients with diplopia, 13 (61%) patients reported an improvement in diplopia after treatment (P <0.05). None of our patients had any adverse event due to systemic steroid and retroorbital radiotherapy. Conclusions: Pulse intravenously applied methylprednisolone for 3 days as 1 gram/day, combined with retroorbital radiotherapy proved to be effective in control of moderate to severe and active thyroid associated ophthalmopathy. In the 6-month follow-up significant decrease in clinical activity score and improvement in diplopia was observed in addition to improvement in best corrected visual acuity.

🔖

Cite This Article

OTO, B. B., OKSUZ, D. C., SERT, S., UZEL, O. E., SARİCİ, A. M. (2023). Clinical Results of Combined Systemic Steroid and Retroorbital Radiotherapy Treatment in Active Thyroid Associated Ophthalmopathy. Dicle Tıp Dergisi, Cilt: 50 Sayı: 2 - Cilt 50, Sayı 2, 149–155. https://ajindex.com/articles/939507

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ginsberg J. Diagnosis and management of Graves'disease. CMAJ. 2003 Mar 4
  2. 168(5):575-85. 2.Bahn RS. Graves' ophthalmopathy. N Engl J Med.2010 Feb 25
  3. 362(8):726-38. doi: 10.1056/NEJMra0905750. 3.Bartalena L, Tanda ML, Bogazzi F, et al. An update onthe pharmacological management of hyperthyroidismdue to Graves' disease. Expert Opin Pharmacother.2005 Jun
  4. 6(6):851-61. doi:10.1517/14656566.6.6.851. 4.Marcocci C, Bartalena L, Bogazzi F, Panicucci M,Pinchera A. Studies on the occurrence ofophthalmopathy in Graves' disease. Acta Endocrinol(Copenh). 1989 Apr
  5. 120(4):473-8. doi:10.1530/acta.0.1200473. 5.Bartalena L, Pinchera A, Marcocci C. Management ofGraves' ophthalmopathy: reality and perspectives.Endocr Rev. 2000 Apr
  6. 21(2):168-99. doi:10.1210/edrv.21.2.0393. 6.Gunji K, Kubota S, Stolarski C, et al. A 63 kDa skeletalmuscle protein associated with eye muscleinflammation in Graves' disease is identified as thecalcium binding protein calsequestrin. Autoimmunity.1999
  7. 29(1):1-9. doi: 10.3109/08916939908995967. 7.Wall JR, Lahooti H. Pathogenesis of thyroid eyedisease - does autoimmunity against the TSH receptorexplain all cases? Endokrynol Pol. 2011
  8. 62 Suppl 1:1-7. 8.Douglas RS, Gianoukakis AG, Kamat S, Smith TJ.Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for diseasepathogenesis. J Immunol. 2007 Mar 1
  9. 178(5):3281-7.doi: 10.4049/jimmunol.178.5.3281. 9.Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbitalfibroblasts in primary culture. J Clin Endocrinol Metab.1996 Sep
  10. 81(9):3428-31. doi:10.1210/jcem.81.9.8784110. 10.Bahn RS. Clinical review 157: Pathophysiology ofGraves' ophthalmopathy: the cycle of disease. J ClinEndocrinol Metab. 2003 May
  11. 88(5):1939-46. doi:10.1210/jc.2002-030010. 11.Bartalena L, Marcocci C, Manetti L, et al. Orbitalradiotherapy for Graves' ophthalmopathy. Thyroid.1998 May
  12. 8(5):439-41. doi: 10.1089/thy.1998.8.439 12.Wang Y, Zhou H, Fan X. The effect of orbitalradiation therapy on thyroid-associated orbitopathycomplicated with dysthyroid optic neuropathy. FrontMed. 2017 Sep
  13. 11(3):359-364. doi: 10.1007/s11684-017-0528-5. 13.Gillis CC, Chang EH, Al-Kharazi K, Pickles T.Secondary malignancy following radiotherapy forthyroid eye disease. Rep Pract Oncol Radiother. 2016May-Jun
  14. 21(3):156-61. doi: 10.1016/j.rpor.2016.01.001.
  15. Haenssle HA, Richter A, Buhl T, et al. Pigmentedbasal cell carcinomas 15 years after orbi